SAFFRON
What it tests: Osimertinib + savolitinib vs platinum–pemetrexed in EGFRm, MET-overexpressed/amplified advanced NSCLC after osimertinib
4Sight: SAFFRON
All ESMO 2026 4Sights
In brief
Osimertinib + Savolitinib vs Platinum–Pemetrexed in EGFRm MET-Overexpressed and/or -Amplified Advanced NSCLC Post-Osimertinib: SAFFRON Phase 3 Primary Results
Phase 3 (n=338): osimertinib + savolitinib vs platinum–pemetrexed in EGFRm, MET-overexpressed and/or amplified advanced NSCLC after osimertinib. Primary endpoint: PFS by BICR.
- Median PFS 7.6 vs 5.4 mo; HR 0.55 (0.42–0.72); p<0.001
- Median OS 17.8 vs 12.9 mo; HR 0.68 (0.50–0.91); p=0.010
- Grade ≥3 TRAEs 40% vs 52%; serious TEAEs 41% vs 28%
- Significant PFS and OS improvement with a manageable safety profile, establishing a new global standard of care.
Shun Lu
Nicolas Girard · Yusuke Okuma